[
  {
    "clinical_recommendation": {
      "alternative_drugs": [
        "Morphine",
        "Hydromorphone",
        "Oxycodone",
        "Tramadol"
      ],
      "guideline_source": "CPIC",
      "recommendation": "Use label-recommended dosage. Monitor for reduced efficacy."
    },
    "drug": "CODEINE",
    "llm_generated_explanation": {
      "mechanism": "CYP2D6 converts codeine to morphine (active form). IM metabolizers may experience altered pain relief.",
      "summary": "Genetic analysis reveals IM phenotype for CYP2D6, classifying CODEINE risk as Adjust Dosage. This assessment is based on 2 detected variant(s) that affect drug metabolism and clinical response.",
      "variant_impact": "Variants identified: rs3892097, rs1065852. These genetic variations in CYP2D6 modify enzyme activity, leading to the IM metabolizer classification and corresponding Adjust Dosage risk profile for CODEINE therapy."
    },
    "patient_id": "PATIENT_32A95547",
    "pharmacogenomic_profile": {
      "detected_variants": [
        {
          "allele": "*4",
          "gene": "CYP2D6",
          "rsid": "rs3892097"
        },
        {
          "allele": "*10",
          "gene": "CYP2D6",
          "rsid": "rs1065852"
        }
      ],
      "diplotype": "*4/*10",
      "phenotype": "IM",
      "primary_gene": "CYP2D6"
    },
    "quality_metrics": {
      "confidence_level": "high",
      "missing_annotations": false,
      "vcf_parsing_success": true
    },
    "risk_assessment": {
      "confidence_score": 0.95,
      "risk_label": "Adjust Dosage",
      "severity": "moderate"
    },
    "timestamp": "2026-02-19T15:37:18.541664Z"
  },
  {
    "clinical_recommendation": {
      "alternative_drugs": [
        "Apixaban",
        "Rivaroxaban",
        "Dabigatran"
      ],
      "guideline_source": "CPIC",
      "recommendation": "Reduce initial dose by 10-25%. Monitor INR closely."
    },
    "drug": "WARFARIN",
    "llm_generated_explanation": {
      "mechanism": "CYP2C9 metabolizes warfarin. IM status affects dosing requirements and bleeding risk.",
      "summary": "Genetic analysis reveals IM phenotype for CYP2C9, classifying WARFARIN risk as Adjust Dosage. This assessment is based on 2 detected variant(s) that affect drug metabolism and clinical response.",
      "variant_impact": "Variants identified: rs1799853, rs1057910. These genetic variations in CYP2C9 modify enzyme activity, leading to the IM metabolizer classification and corresponding Adjust Dosage risk profile for WARFARIN therapy."
    },
    "patient_id": "PATIENT_32A95547",
    "pharmacogenomic_profile": {
      "detected_variants": [
        {
          "allele": "*2",
          "gene": "CYP2C9",
          "rsid": "rs1799853"
        },
        {
          "allele": "*3",
          "gene": "CYP2C9",
          "rsid": "rs1057910"
        }
      ],
      "diplotype": "*2/*3",
      "phenotype": "IM",
      "primary_gene": "CYP2C9"
    },
    "quality_metrics": {
      "confidence_level": "high",
      "missing_annotations": false,
      "vcf_parsing_success": true
    },
    "risk_assessment": {
      "confidence_score": 0.95,
      "risk_label": "Adjust Dosage",
      "severity": "moderate"
    },
    "timestamp": "2026-02-19T15:37:18.902358Z"
  },
  {
    "clinical_recommendation": {
      "alternative_drugs": [
        "Prasugrel",
        "Ticagrelor"
      ],
      "guideline_source": "CPIC",
      "recommendation": "Consider alternative antiplatelet or increased dose per guidelines."
    },
    "drug": "CLOPIDOGREL",
    "llm_generated_explanation": {
      "mechanism": "CYP2C19 activates clopidogrel to its active form. IM metabolizers may have reduced antiplatelet effect.",
      "summary": "Genetic analysis reveals IM phenotype for CYP2C19, classifying CLOPIDOGREL risk as Adjust Dosage. This assessment is based on 2 detected variant(s) that affect drug metabolism and clinical response.",
      "variant_impact": "Variants identified: rs4244285, rs12248560. These genetic variations in CYP2C19 modify enzyme activity, leading to the IM metabolizer classification and corresponding Adjust Dosage risk profile for CLOPIDOGREL therapy."
    },
    "patient_id": "PATIENT_32A95547",
    "pharmacogenomic_profile": {
      "detected_variants": [
        {
          "allele": "*2",
          "gene": "CYP2C19",
          "rsid": "rs4244285"
        },
        {
          "allele": "*17",
          "gene": "CYP2C19",
          "rsid": "rs12248560"
        }
      ],
      "diplotype": "*2/*17",
      "phenotype": "IM",
      "primary_gene": "CYP2C19"
    },
    "quality_metrics": {
      "confidence_level": "high",
      "missing_annotations": false,
      "vcf_parsing_success": true
    },
    "risk_assessment": {
      "confidence_score": 0.95,
      "risk_label": "Adjust Dosage",
      "severity": "moderate"
    },
    "timestamp": "2026-02-19T15:37:19.256579Z"
  },
  {
    "clinical_recommendation": {
      "alternative_drugs": [
        "Pravastatin",
        "Rosuvastatin",
        "Atorvastatin"
      ],
      "guideline_source": "CPIC",
      "recommendation": "Reduce dose or consider alternative statin."
    },
    "drug": "SIMVASTATIN",
    "llm_generated_explanation": {
      "mechanism": "SLCO1B1 transporter affects simvastatin uptake. IM status influences myopathy risk.",
      "summary": "Genetic analysis reveals IM phenotype for SLCO1B1, classifying SIMVASTATIN risk as Adjust Dosage. This assessment is based on 1 detected variant(s) that affect drug metabolism and clinical response.",
      "variant_impact": "Variants identified: rs4149056. These genetic variations in SLCO1B1 modify enzyme activity, leading to the IM metabolizer classification and corresponding Adjust Dosage risk profile for SIMVASTATIN therapy."
    },
    "patient_id": "PATIENT_32A95547",
    "pharmacogenomic_profile": {
      "detected_variants": [
        {
          "allele": "*5",
          "gene": "SLCO1B1",
          "rsid": "rs4149056"
        }
      ],
      "diplotype": "*5/*1",
      "phenotype": "IM",
      "primary_gene": "SLCO1B1"
    },
    "quality_metrics": {
      "confidence_level": "high",
      "missing_annotations": false,
      "vcf_parsing_success": true
    },
    "risk_assessment": {
      "confidence_score": 0.95,
      "risk_label": "Adjust Dosage",
      "severity": "moderate"
    },
    "timestamp": "2026-02-19T15:37:19.554445Z"
  },
  {
    "clinical_recommendation": {
      "alternative_drugs": [
        "Mycophenolate",
        "Methotrexate"
      ],
      "guideline_source": "CPIC",
      "recommendation": "Reduce dose to 10% of standard. Monitor closely for toxicity."
    },
    "drug": "AZATHIOPRINE",
    "llm_generated_explanation": {
      "mechanism": "TPMT metabolizes azathioprine. PM metabolizers have altered toxicity risk.",
      "summary": "Genetic analysis reveals PM phenotype for TPMT, classifying AZATHIOPRINE risk as Toxic. This assessment is based on 1 detected variant(s) that affect drug metabolism and clinical response.",
      "variant_impact": "Variants identified: rs1142345. These genetic variations in TPMT modify enzyme activity, leading to the PM metabolizer classification and corresponding Toxic risk profile for AZATHIOPRINE therapy."
    },
    "patient_id": "PATIENT_32A95547",
    "pharmacogenomic_profile": {
      "detected_variants": [
        {
          "allele": "*3A",
          "gene": "TPMT",
          "rsid": "rs1142345"
        }
      ],
      "diplotype": "*3A/*1",
      "phenotype": "PM",
      "primary_gene": "TPMT"
    },
    "quality_metrics": {
      "confidence_level": "high",
      "missing_annotations": false,
      "vcf_parsing_success": true
    },
    "risk_assessment": {
      "confidence_score": 0.95,
      "risk_label": "Toxic",
      "severity": "high"
    },
    "timestamp": "2026-02-19T15:37:19.871757Z"
  },
  {
    "clinical_recommendation": {
      "alternative_drugs": [
        "Capecitabine (with caution)",
        "Raltitrexed"
      ],
      "guideline_source": "CPIC",
      "recommendation": "Avoid fluorouracil. High risk of severe toxicity."
    },
    "drug": "FLUOROURACIL",
    "llm_generated_explanation": {
      "mechanism": "DPYD metabolizes fluorouracil. PM status significantly affects toxicity risk.",
      "summary": "Genetic analysis reveals PM phenotype for DPYD, classifying FLUOROURACIL risk as Toxic. This assessment is based on 1 detected variant(s) that affect drug metabolism and clinical response.",
      "variant_impact": "Variants identified: rs3918290. These genetic variations in DPYD modify enzyme activity, leading to the PM metabolizer classification and corresponding Toxic risk profile for FLUOROURACIL therapy."
    },
    "patient_id": "PATIENT_32A95547",
    "pharmacogenomic_profile": {
      "detected_variants": [
        {
          "allele": "*2A",
          "gene": "DPYD",
          "rsid": "rs3918290"
        }
      ],
      "diplotype": "*2A/*1",
      "phenotype": "PM",
      "primary_gene": "DPYD"
    },
    "quality_metrics": {
      "confidence_level": "high",
      "missing_annotations": false,
      "vcf_parsing_success": true
    },
    "risk_assessment": {
      "confidence_score": 0.95,
      "risk_label": "Toxic",
      "severity": "high"
    },
    "timestamp": "2026-02-19T15:37:20.353719Z"
  }
]